These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 11858973)
21. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Raemaekers J; Kluin-Nelemans H; Teodorovic I; Meerwaldt C; Noordijk E; Thomas J; Glabbeke Mv; Henry-Amar M; Carde P Eur J Cancer; 2002 Mar; 38 Suppl 4():S107-13. PubMed ID: 11858975 [TBL] [Abstract][Full Text] [Related]
22. Allan van Oosterom, President of the EORTC. European Organisation for the Research and Treatment of Cancer. Interview by Jeroen van der Boon. van Oosterom A Lancet Oncol; 2002 Jan; 3(1):58-61. PubMed ID: 11905607 [No Abstract] [Full Text] [Related]
23. Regulatory issues for clinical trials at EORTC: the way forward. European Organisation for Research and Treatment of Cancer. Baeyens AJ; Lacombe D Eur J Cancer; 2002 Mar; 38 Suppl 4():S142-6. PubMed ID: 11858981 [TBL] [Abstract][Full Text] [Related]
24. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N; Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702 [TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092 [TBL] [Abstract][Full Text] [Related]
26. The Children Leukemia Group: 30 years of research and achievements. Otten J; Philippe N; Suciu S; Béhar C; Babin-Boilletot A; Thyss A; Ferster A; Vilmer E; Eur J Cancer; 2002 Mar; 38 Suppl 4():S44-9. PubMed ID: 11858964 [TBL] [Abstract][Full Text] [Related]
27. [European Organization for Research and Treatment of Cancer (EORTC): objectives, realizations and future perspectives]. Meunier F Bull Mem Acad R Med Belg; 1992; 147(8-9):334-42; discussion 342-4. PubMed ID: 1286412 [TBL] [Abstract][Full Text] [Related]
28. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. Bryant AL; Drier SW; Lee S; Bennett AV Leuk Res; 2018 Jul; 70():106-116. PubMed ID: 29925044 [TBL] [Abstract][Full Text] [Related]
29. Achievements and goals of the EORTC Invasive Fungal Infections Group. European Organisation for Research and Treatment of Cancer. de Pauw BE; Herbrecht R; Meunier F; Eur J Cancer; 2002 Mar; 38 Suppl 4():S88-93. PubMed ID: 11858972 [TBL] [Abstract][Full Text] [Related]
30. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee. Lardot C; Steward W; Van Glabbeke M; Armand JP Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960 [TBL] [Abstract][Full Text] [Related]
31. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). Viscoli C; Eur J Cancer; 2002 Mar; 38 Suppl 4():S82-7. PubMed ID: 11858971 [TBL] [Abstract][Full Text] [Related]
32. EORTC cutaneous lymphoma task force. European Organisation for Research and Treatment of Cancer. Knobler R; Burg G; Whittaker S; Baila L Eur J Cancer; 2002 Mar; 38 Suppl 4():S60-4. PubMed ID: 11858967 [TBL] [Abstract][Full Text] [Related]
33. Quality assurance in surgical oncology (QASO) within the European Organization for Research and Treatment of Cancer (EORTC): current status and future prospects. Landheer ML; Therasse P; van de Velde CJ Eur J Cancer; 2001 Aug; 37(12):1450-62. PubMed ID: 11506950 [TBL] [Abstract][Full Text] [Related]
34. The EORTC Gastrointestinal Tract Cancer Group: 40 years of research contributing to improved GI cancer management. Anak O; Van Cutsem E; Nordlinger B Eur J Cancer; 2002 Mar; 38 Suppl 4():S65-70. PubMed ID: 11858968 [TBL] [Abstract][Full Text] [Related]
35. Advancing a field by building consortia: The example of the European LeukemiaNet. Hehlmann R Cancer; 2018 Mar; 124(6):1100-1104. PubMed ID: 29451688 [No Abstract] [Full Text] [Related]
36. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? Cannella L; Caocci G; Jacobs M; Vignetti M; Mandelli F; Efficace F Crit Rev Oncol Hematol; 2015 Dec; 96(3):542-54. PubMed ID: 26324461 [TBL] [Abstract][Full Text] [Related]
37. Workshop of the EORTC Radiotherapy Group on quality assurance in cooperative trials of radiotherapy: a recommendation for EORTC Cooperative Groups. Johansson KA; Hanson WF; Horiot JC Radiother Oncol; 1988 Mar; 11(3):201-3. PubMed ID: 3363167 [No Abstract] [Full Text] [Related]
39. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954 [TBL] [Abstract][Full Text] [Related]
40. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Bennett JM Int J Hematol; 2000 Aug; 72(2):131-3. PubMed ID: 11039659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]